Detail page

Knowledge Web

Person

Tim Henrik Brümmendorf (1966-)

Arzt

Name	Tim Henrik Brümmendorf
Time	1966- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession) Onkologe
Variant	Tim H. Brümmendorf Tim Brümmendorf
Related	Universitätsklinikum Hamburg-Eppendorf
Further information	Habil. Fach Innere Medizin, Univ. Tübingen, 2004 Univ. Hamburg, Medizinische Fak., Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, II. Medizinische Klinik und Poliklinik; Universitäres Cancer Center Hamburg (UCCH) seit 2009 Uniklinikum Aachen
Record type	Person
GND-Identifier	115060219
Record ID	115060219
Involved in show all Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : : Protocol of a prospective multicenter phase 2 trial = Kombination von Nivolumab mit Standard-Induktionschemotherapie bei Kindern und Erwachsenen mit EBV-positivem Nasopharynxkarzinom : Protokoll einer prospektiven multizentrischen Phase-II-Studie Effectiveness of a comprehensive support program for families with parental cancer (Family-SCOUT) : results of a multicenter non-randomized controlled trial Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals : analysis on 6849 participants of the SHIP-study Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy Revesz syndrome revisited Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH) A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia Bosutinib : ein neuartiger BCR-ABL-Inhibitor bei vorbehandelten Patienten mit CML Protein-protein-interaction network organization of the hypusine modification system Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation Telomerbiologie und zelluläre Alterung in der gesunden und pathologisch gesteigerten Hämatopoese Immunszintigraphie xenotransplantierter gynäkologischer Tumoren mit monoklonalen Anti-Muzinantikörpern

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Tim Henrik Brümmendorf (1966-)

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry

Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Effectiveness of a comprehensive support program for families with parental cancer (Family-SCOUT) : results of a multicenter non-randomized controlled trial

Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia

Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals : analysis on 6849 participants of the SHIP-study

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study

XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy

Revesz syndrome revisited

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition

DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

Bosutinib : ein neuartiger BCR-ABL-Inhibitor bei vorbehandelten Patienten mit CML

Protein-protein-interaction network organization of the hypusine modification system

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro

Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

Telomerbiologie und zelluläre Alterung in der gesunden und pathologisch gesteigerten Hämatopoese

Immunszintigraphie xenotransplantierter gynäkologischer Tumoren mit monoklonalen Anti-Muzinantikörpern